Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Women's Health Science Journal Research Article 19 min read

Management of HBV/HIV Co-Infection

Haider R*
* Corresponding author
ISSN: 2639-2526  10.23880/whsj-16000187  Received: September 28, 2023  Published: October 30, 2023
 — views
 56 references
PDF
Keywords
Liver/Hepatitis Antiretroviral Therapy Antiviral Therapy Pathogenesis Reverse Transcriptase Inhibitors
Abstract

Co-infection with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) represents a complex and dispassionate challenge that demands a versatile approach. This abstract specifies a survey of key strategies for the administration of HBV/ HIV co-contamination, accompanied by a devoted effort to antiretroviral healing (ART), the HBV situation, and listening. Antiretroviral therapy is the foundation for directing hepatitis B virus (HBV)/HIV contamination. The incorporation of HIVHBV drugs into ART regimens is essential. Tenofovir-located regimens containing tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) have proven to be effective against both viruses. Emtricitabine and lamivudine are frequently used in combination medicine. Monitoring drug opposition and energy abolition is achieved by guaranteeing the influence of the treatment. In HBV mono-infection, nucleotide analogs (NA) are used to restrain energetic copies. However, in cocontamination, NAs concede the possibility of ideally having a two-fold project against both HIV and HBV infection. TDF and TAF meet this necessity, making the ruling class the chosen choice. Regular listening is essential for evaluating the reaction to the situation and the progress of a liver ailment. This involves measuring the CD4 counts, HIV RNA levels, and HBV DNA levels. In addition, liver function tests and liver depictions help label cirrhosis and abnormal hepatocellular growth in animals. HBV immunization is essential for co-infected cells that are not resistant to HBV. Post-vaccination agents that negate the effect of an infection or poison titer should be restrained to ratify exemption. The prevention of broadcasting is another critical aspect of the administration. Safe sexuality practices and harm decline methods, including tease exchange programs for injecting drug use, detract from lowering the risk of transmission of the two viruses together.

Introduction

The prevalence and routes of transmission of hepatitis B virus (HBV) co-infection in the HIV+ population vary considerably by geographic area [1, 2]. In the United States and Europe, most HIV-positive gay men have evidence of past HBV infection, and 5–10% show persistence of the HBs antigen, with or without replicative hepatitis B, as defined by the presence of HBV DNA. Overall, HBV/HIV coinfection rates are slightly lower in IDUs than in gay men and much lower in heterosexually infected people [3]. In endemic areas of Africa and Asia, most HBV infections are transmitted vertically at birth or before the age of 5 years through close household contact, medical procedures, and traditional scarification [4]. The prevalence among youth in most Asian countries has decreased substantially since vaccination was introduced nationwide [5]. In Europe, vaccination of children and members of risk groups is supported and paid for by the health systems in most countries. The natural history of hepatitis B is altered by current HIV infection. HBV immune control is negatively affected, leading to a decrease in HBsAg seroconversion. HBV DNA levels are generally higher in HIV- positive patients who are not on antiretroviral therapy Bods, Bods, [6, 7, 8], and as cellular immune deficiency progresses, HBV replication is reactivated despite previous HB antigen seroconversion [9]. However, after immune recovery due to antiretroviral therapy, He-antigen, and HBs-antigen seroconversion occurs in a higher proportion of patients than in HBV-monoinfected patients treated for chronic hepatitis B [10, 11, 12]. In untreated HIV infection, HBV/HIV co- infected patients have been reported to progress more rapidly to cirrhosis [13], hepatocellular carcinoma can develop at an earlier age and is more aggressive in this population [14, 15]. Introduction: HBV coinfection results in increased mortality in HIV-positive individuals, even after the introduction of effective antiretroviral therapy (ART), as demonstrated by an analysis of the EuroSIDA Study, which showed a 3.6-fold higher risk of liver-related deaths among HBsAg-positive patients compared to HBsAg-negative individuals [16]. In the Multicenter AIDS Cohort Study (MACS), an 8-fold increased risk of liver-related mortality was observed among HBV/HIV co-infected individuals, particularly among subjects with low nadir CD4+ cell counts [17]. Even at present, despite the widespread use of tenofovir, HBV/HIV co-infection is still associated with increased morbidity [18], and liver-related deaths in HBV/HIV-infected patients still occur [19]. The beneficial impact of HBV treatment in HBV/HIV co-infection was first demonstrated by data from a large cohort showing a reduction in mortality with lamivudine treatment compared to untreated patients, which is even more remarkable because lamivudine is the least effective HBV polymerase inhibitor owing to the rapid development of drug resistance. In general, because of its limited long-term efficacy, lamivudine monotherapy cannot be considered an appropriate therapy for either mono HBV infection or HBV/HIV coinfection [20]. In addition, two large cohort studies (EuroSIDA and MACS) plus data from HBV mono-infection studies showing a reduction in morbidity and mortality established the need to treat chronic hepatitis B in HBV/HIV-co-infected patients [21, 22]. Treatment of chronic hepatitis B in HBV/HIV-co-infected patients on antiretroviral therapy In the well-known, beginning hepatitis B therapy depends on the diploma of liver fibrosis and HBV DNA level. Craftsmanship is now heartened for all HIV inmates who are not CD4 counted to lower HIV-accompanying morbidity and death, and for fear that HIV broadcast, all HBV/HIV co-infected sufferers are thought-out fit for art accompanying, utilizing the ultimate up-to-date recommendation (e.g., occurring in 2016). Previous complicated pieces of advice to handle constant hepatitis B in patients with no painting on coarse material were old- fashioned. Since antiretroviral capsules can usually be obtained secondhand, which may also exist for HBV, total interferon-located HBV treatment is immediately and infrequently indicated. Enumerations in research on HIV- coinfected cases on interferon treatment for HBV contamination are calm and not encouraging. Furthermore, a more exhaustive search of the situation with consolidation of pegylated interferon accompanying adefovir or intensification of TDF analysis accompanying pegylated interferon for 12 months rooted no boom in HBV seroconversion citations [23, 24]. Tenofovir is generally the typical treatment for HBV in HIV-polluted patients through allure, forceful affinity for HBV polymerase, and antiretroviral exercise. Tenofovir has been a long-acting and effective medicine in the broad plurality of patients accompanying HBV/HIV co-contamination [25, 26, 27]. Its antiviral efficacy is not lowered in HBV/HIV co-contaminated patients compared to that in HBV monoinfected patients [28]. No final pattern of fighting mutations was acknowledged in the research or cohorts [29]. Nevertheless, these dossiers were authentic as of late 2016. Resistance continues to persist in patients on general cure, accompanied by other antivirals. No routine protocol is recommended for cases with HBV DNA < 2000 IU/mL and outside-appropriate liver fibrosis. However, owing to its benign fighting profile, rutin, in addition to tenofovir, was the first inclination. When selecting an HBV polymerase inhibitor, the complete abolition of HBV DNA is necessary to prevent the development of HBV drug resistance. While HBV DNA is above 2000 IU/mL in Ide-naïve inmates, a combination of tenofovir plus lamivudine/emtricitabine is usually recommended for each infection. This approach still applies to inmates who harbor HBV resistance to lamivudine, telbivudine, or adefovir because of their former situational plans. The recommendation to hold lamivudine or emtricitabine generally establishes residual opposition to adefovir, that is to say, seen [30], but the unchanging impact was no longer evident with tenofovir [31]. Arising skill, tenofovir, resulted in higher rates of HBe irritant loss and seroconversion, also known as HBV mono-contamination. This suggests the possibility of a supplementary effect of immune rearrangement in HBV/HIV co-polluted subjects, complicating the immunological control of HBV copies. In patients with advanced liver fibrosis or liver cirrhosis, maximum live continuous HBV polymerase prevention medicine is mainly used to prevent further progression of fibrosis and liver decompensation, and to lower the risk of expanding hepatocellular carcinoma. The choice was tenofovir plus lamivudine/emtricitabine. If the results are not completely suppressed, the addition of entecavir should be considered [32]. A reduction in the occurrence of abnormal hepatocellular growth in animals has been demonstrated in cases taking HBV polymerase inhibitors compared with untreated cases, strengthening the antiproliferative properties of suppressive antiviral healing [33]. A liver ultrasound is not completed every six months for the early discovery of abnormal hepatocellular growth in animals. Esophago gastroscopy should be performed in patients with advanced cirrhosis due to esophageal changes, and liver transplantation should be deliberate for victims accompanying hepatic decompensation and full HBV situation alternatives who have fixed HIV contamination, as post-relocation survival performance is expected to be complementary to that of HBV mono-infected inmates [34, 35]. Patients with abnormal hepatocellular growth in animals may be more likely to be considered candidates for liver transplantation, even though preliminary notes from limited cohorts suggest that the effect may be worse than that in cases contaminated with HBV mono (Vibert, 2008). In prospective reserved tests, tenofovir was found to be superior to adefovir for the treatment of HBe irritant-certain and HBe antigen-negative victims [36]. Acquisition of adefovir fighting mutations and diversified lamivudine resistance mutations can hinder tenofovir action [37] although even in these positions, tenofovir retains adequate exercise against HBV [38, 39, 40]. In lamivudine-resistant HBV, the antiviral efficiency of entecavir in HIV-coinfected victims.

The number of patients is reduced, as is the case with HBV mono-infection. Because of this and the property of tenofovir as a fully active antiretroviral, tenofovir DF is the preferred choice in treatment-naïve HBV/HIV co-infected patients who will use ART. The use of entecavir, telbivudine, or adefovir as an add-on to tenofovir or other drugs in the case of non-fully suppressive antiviral HBV therapy has not yet been studied in HBV/HIV co-infection. This decision must be made on a case-by-case basis. Based on the history of ART, combination HBV therapy with tenofovir plus lamivudine/emtricitabine is expected to be superior to tenofovir monotherapy, particularly in patients with highly replicative HBV infection. However, this hypothesis has not yet been supported by other studies [41, 42, 43, 44]. Data show better viral suppression for entecavir and tenofovir-DF compared with entecavir monotherapy in highly replicative patients infected with HBV-mono mono, but no such study is available for comparison with tenofovir monotherapy [45]. In the case of HIV resistance to tenofovir, it is usually important to continue using tenofovir for HBV activity when switching to other ART. Discontinuation of the HBV polymerase inhibitor without maintaining antiviral pressure on HBV can lead to necro-inflammatory flares that can result in acute liver decompensation, particularly in patients with liver cirrhosis. In 2015, tenofovir alafenamide (TAF) was approved as an antiretroviral therapy in Europe and the US. TAF is a new formulation of tenofovir with lower plasma exposure to the active drug tenofovir than to tenofovir diproxovil fumarate (TDF). TAF has not shown superior antiviral activity against HIV or HBV compared to TDF but may offer advantages concerning long-term toxicities involving the bone and kidney over TDF [46, 47]. TAF can substitute TDF for HBV therapy in HBV/HIV-coinfected patients [48]. In November 2016, TAF was approved for HBV treatment in the US, followed by approval in Europe in January 2017. The potential nephrotoxic effects of TDF are concerning. Although nephrotoxicity is rarely observed in HIV-negative patients treated with TDF monotherapy [49, 50] renal impairment has been more frequently reported in HIV-positive patients using TDF as a component in ART and may be associated in particular with the combined use of TDF and ritonavir-boosted HIV protease inhibitors [51, 52, 53, 54, 55, 56]. In addition, the recently approved cytochrome P450 3A inhibitor cobicistat can also increase creatinine levels. Regular monitoring of renal function in HBV/HIV-co-infected patients, including the estimated glomerular filtration rate (eGFR) and assessment of proteinuria, is necessary. In the case of reduced eGFR, TDF should be substituted by TAF or should be dosed at a reduced frequency according to the label. In cases of significant proteinuria, TDF should be replaced with TAF. Alternatively, in specific situations in the case of tenofovir-associated nephrotoxicity, tenofovir can also be replaced by entecavir.

Research Methods

Study design: e.g., clinical trial, observational study, retrospective analysis. Participants: Description of the study population, including the number of individuals with HBV/ HIV co-infection and their characteristics. Interventions: Details of the treatments or interventions applied (e.g., antiretroviral therapy, anti-HBV drugs).

Data collection

Methods used to collect data included laboratory tests, imaging, and clinical assessments. Data analysis: Statistical methods used to analyze the data. Results: Findings related to the study’s primary objectives are presented.

Result

Virological response, immunological response, and liver function improvement. Adverse events: any side effects or complications observed during treatment.

Discussion

Interpretation of the results and comparison with previous research. Implications: What do these findings mean for the management of HBV/HIV co-infection? Limitations: Addressing any shortcomings or biases in the study design or data collection. Future directions: Suggestions for further research or potential improvements in management strategies.

Conclusion

The number of vacant HBV polymerase inhibitors for never-ending hepatitis B has increased over the past few years. In general, the choice is confined to two non-cross- opposing classes: the nucleotide and nucleoside compounds HBV/HIV co-polluted inmates. ART is used to treat two types of contamination. The HBV treatment of choice is tenofovir. Due to the rapid occurrence of fighting when HBV is not completely restrained, HBV monotherapy with either lamivudine or emtricitabine should not be considered. An alliance of tenofovir plus lamivudine or emtricitabine as a basic blend cure has hypothetical benefits over tenofovir alone; however, studies upholding this concept have not yet been conducted. However, since tenofovir is associated with emtricitabine or lamivudine, private antiretroviral procedures are contemporary. This appears to be a hypothetical debate and is not mirrored by matter. In general, the situation of HBV as an aggressive affliction follows the same rules as HIV cure, disposing of adequate abolition of the bug copy to prevent the incidence of resistance. Successfully circulating the abolition of hepatitis B results in the hindrance of necro-angering projects, the reversal of fibrosis, and most importantly, a decrease in the occurrence of hepatic decompensation and hepatocellular carcinoma.

Acknowledgment

The finishing touches concerning this research appointment were taken care of immediately, likely outside the contributions and help of many things and groups. We’re. I would like to thank my mentors, Dr. Naweed Imam Syed and Prof. Arm of Travel Biology at the University of Calgary, for their beneficial recommendations and counseling during the intervention period of the research plan. Their understanding has been assisting in forming a way concerning this endeavor.

Authors Contribution

I would like to increase our honest habit to all the appendages of our take a look at, the one who liberally joins their occasion, studies, and judgments accompanying us. Their readiness to communicate with our studies is enhanced by their happiness concerning this responsibility, and we are intensely appreciative of their partnerships.

References

  1. Alter M (2006) Epidemiology of vigorous hepatitis and HIV co-infection J Hepatol 44(1): 6-9.
  2. Konopnicki D, Mocroft A, Wit DS, Antunes F, Ledergerber B, et al. (2005) Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort AIDS 19(6): 593-601.
  3. Nunez M, Puoti M, Camino N, Soriano V (2003) Treatment of never ending hepatitis B in a human immunodeficiency bacterium contaminated patient present and future. Clin Infect Dis 37: 1678-1685.
  4. Modi A, Feld J (2007) Viral hepatitis and HIV Infection in Africa. AIDS Rev 9: 25-39.
  5. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2008) Hepatitis B bacterium contamination community health and immunization Epidemiology and others Entecavir situation in lamivudine obstinate incessant hepatitis B revised virologic biochemical and serologic consequences over 96 weeks Hepatology. 48: 99-108.
  6. Bods worth N, Donovan B, Nightingale BN (1989) The effect of concurrent human immunodeficiency virus infection on chronic hepatitis B a study of 150 homosexual men. J Infect Dis 160: 577-582.
  7. Bodsworth NJ, Cooper DA, Donovan B (1991) The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J Infect Dis 163(5): 1138-1140.
  8. Hadler SC, Judson FN, Malley PM, Altman NL, Penley K, et al. (1991) Outcome of hepatitis B bug contamination in sexually attracted to the same sex sons and allure connection to earlier human immunodeficiency bacterium contamination. J Infect Dis 163: 454-459.
  9. Soriano V, Puoti M, Bonacini M (2005) Care of victims accompanying incessant hepatitis B and HIV coinfection pieces of advice from the worldwide HIV HBV committee. AIDS 19: 221-240.
  10. Schmutz G, Nelson M, Lutz T, Julie S, Bruno R, et al. (2006) Combination of tenofovir and lamivudine against tenofovir and later breakdown of lamivudine in the situation of hepatitis B in HIV co contamination AIDS. 20: 1951-1954.
  11. Piroth L, Pol S, Lacombe K, Miailhes P, Rami V, et al. (2010) Management and situation of incessant hepatitis B bug contamination in HIV positive and negative inmates EPIB study 2008. J Hepatol 53(6): 1006-1012.
  12. Kosi L, Reiberger T, Payer B, Pfistershammer KG, Strassl R, et al. (2012) Five period productiveness of lamivudine tenofovir and tenofovir emtricitabine located HAART in HIV HBV coinfected cases. J Viral Hepat 19(11): 801-810.
  13. Puoti M, Torti C, Bruno R (2006) Natural history of incessant hepatitis Bincontaminated cases. J Hepatol 44: 65-70.
  14. Puoti M, Bruno R, Soriano V (2004) Hepatocellular abnormal growth in animate beings in HIV polluted victims epidemiologic physiognomy dispassionate performance and effect AIDS 18: 2285-2293.
  15. Brau N, Fox R, Xiao P, Marks K, Naqvi Z, et al. (2007) Presentation and consequences of hepatocellular abnormal growth in animate beings in HIV contaminated subjects a US Canadian multicenter study. J Hepatol 47(4): 527-537.
  16. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, et al. (2009) Effect of hepatitis B bug contamination on AIDS progress and humanness in HIV polluted things a comrade study and meta study. Clin Infect Dis 48: 1763-1771.
  17. Thio C, Seaberg E, Skolsky R, John P, Visscher B, et al. (2002) HIV 1 hepatitis B virus and risk of liver related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
  18. Crowell TA, Gebo KA, Balagopal A, John AF, Allison LA, et al. (2014) Impact of hepatitis coinfection on hospitalization rates and causes in a multicenter cohort of persons living with HIV. J Acquir Immune Deficiency Syndr 65(4): 429-437.
  19. Rosenthal E, Roussillon C, Salmon-Ceron D, Georget A, Henard S, et al. (2015) Liver-related deaths in HIV- infected patients between 1995 and 2010 in France: the Mortavic 2010 study in collaboration with the Agence Nationale de Recherche sur le SIDA (ANRS) EN 20 Mortalite 2010 survey. HIV Med 16(4): 230-239.
  20. Matthews GV, Manzini P, Hu Z, Paul K, Patrick M, et al. (2011) Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 1727-1735.
  21. Modi AA, Feld JJ (2007) Viral hepatitis and HIV in Africa. AIDS Rev 9(1): 25-39.
  22. Nunez M, Puoti M, Camino N, Soriano V (2003) Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis 37: 1678-1685.
  23. Ingiliz P, Valantin MA, Thibault V, Duvivier C, Dominguez S, et al. (2008) Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV- infected patients. Antivir Ther 13: 895-900.
  24. Boyd A, Piroth L, Maylin S, Lebosse F, Bouix C, et al. (2016) Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co- infected patients. J Viral Hepat 23(12): 1017-1026.
  25. Van Bommel F, Wunsche T, Mauss S, Reinke P, Bergk A, et al. (2004) Comparison of adefovir and tenofovir for the treatment of lamivudine resistant hepatitis B virus infection. Hepatology 40: 1421-1425.
  26. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, et al. (2009) Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine- experienced HIV/HBV coinfected individuals. AIDS 23: 1707-1715.
  27. Thibault V, Stitou H, Desire N, Valantin MA, Tubiana R, et al. (2011) Six year follow up of hepatitis B surface antigen concentrations in tenofovir disoproxil fumarate treated HIV HBV co infected patients. Antivir Ther 16: 199-205.
  28. Plaza Z, Aguilera A, Mena A, Vispo E, Enguita RS, et al. (2013) Influence of HIV infection on the response to tenofovir in patients with chronic hepatitis B. AIDS 27(14): 2219-2224.
  29. Snow Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, et al. (2011) No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients mono-infected with chronic hepatitis B virus. Hepatology 53: 763-773.
  30. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, et al. (2007) Low resistance to adefovir combined with lamivudine A 3 year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 133: 1445-1451.
  31. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, et al. (2010) Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology 139: 1207-1217.
  32. Ratcliffe L, Beads worth MB, Pennell A, Phillips M, Vilar FJ (2011) Managing hepatitis B HIV co infected adding entecavir to truvada (tenofovir disoproxil/emtricitabine) experienced patients. AIDS 25: 1051-1056.
  33. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, et al. (2013) Long term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58(1): 98-107.
  34. Coffin CS, Stock PG, Dove LM, Berg CL, Nissen NN, et al. (2010) Virologic and clinical outcomes of hepatitis B virus infection in HIV HBV co infected transplant recipients. Am J Transplant 10: 1268-1275.
  35. Tateo M, Roque Afonso AM, Antonini TM, Medja F, Lombes A, et al. (2009) Long term follow up of liver transplanted HIV hepatitis B virus co infected patients perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 23: 1069-1076.
  36. Marcellin P, Heath Cote EJ, Buti M, Gane Ed, Robert AM, et al. (2011) Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B Clinical and virological outcomes in HIV infected patients with chronic hepatitis B on long term nucleotide analogs. AIDS 25: 73-79.
  37. Fung SK, Andreone P, Han SH, Rajender RK, Regev A, et al. (2005) Adefovir resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 43: 937-943.
  38. Berg T, Marcellin P, Zoulim F, Moller B, Trinh H, et al. (2010) Tenofovir is effective alone or with emtricitabine in adefovir treated patients with chronic hepatitis B virus infection. Gastroenterology 139: 1207-1217.
  39. Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, et al. (2011) Tenofovir disoproxil fumarate rescue therapy following the failure of both lamivudine and adefovir digitoxin in chronic hepatitis B. Gut 60: 247-254.
  40. Petersen J, Ratziu V, Buti M, Lampertico P, Brown A, et al. (2012) Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients An international multicenter cohort study. J Hepatol 56(3): 520-526.
  41. Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, et al. (2006) Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV coinfection. AIDS 20(15): 1951-1954.
  42. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, et al. (2008) A randomized trial of combination hepatitis B therapy in HIV HBV co infected antiretroviral naive individuals in Thailand. Hepatology 48(4): 1062-1069.
  43. Matthews GV, Seaberg E, Dore GJ, Bowden S, Lewin SR, et al. (2009) Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine- experienced HIV/HBV-coinfected individuals. AIDS 23(13): 1707-1715.
  44. Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, et al. (2013) Suppression of HBV by tenofovir in HBV/ HIV co-infected patients: a systematic review and meta- analysis. PLoS One 8(7): e68152.
  45. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, et al. (2012) Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology 143(3): 619- 628.
  46. Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, et al. (2015) Twenty-eight-day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 62(3): 533-540.
  47. Sax PE, Wohl D, Yin MT, Post F, Dejesus E, et al. (2015) Tenofovir alafenamide versus tenofovir disoproxil fumarate, co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomized, double-blind, phase 3, non-inferiority trials. Lancet 385(9987): 2606-2615.
  48. Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, et al. (2016) Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 73(3): 294-298.
  49. Heathcote EJ, Marcellin P, Buti M, Gane E, Germanidis G, et al. (2011) Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 140(1): 132-143.
  50. Mauss S, Berger F, Flimann N, Hueppe D, Henke J, et al. (2011) Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 55: 1235-1240.
  51. Mauss S, Berger F, Schmutz G (2005) Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 19(1): 93-95.
  52. Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, et al. (2007) Swiss HIV Cohort Study. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther 12: 1165-1173.
  53. Goicoechea M, Liu S, Best B, Sun S, Jain S, et al. (2008) California Collaborative Treatment Group 578 Team. Greater tenofovir-associated renal function decline with protease inhibitor-based versus non-nucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis 197:102-108.
  54. Mocroft A, Kirk O, Reiss P, De Wit S, Sedlacek D, et al. (2010) Estimated glomerular filtration rate, chronic kidney disease, and antiretroviral drug use in HIV- positive patients. AIDS 24(11): 1667-1678.
  55. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44(1): S6-9.
  56. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, et al. (2005) EuroSIDA Group. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19(6): 593-601.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{haider2023,
  title   = {Management of HBV/HIV Co-Infection},
  author  = {Haider R},
  journal = {Women\'s Health Science Journal},
  year    = {2023},
  volume  = {7},
  number  = {2},
  doi     = {10.23880/whsj-16000187}
}
Haider R (2023). Management of HBV/HIV Co-Infection. Women's Health Science Journal, 7(2). https://doi.org/10.23880/whsj-16000187
TY  - JOUR
TI  - Management of HBV/HIV Co-Infection
AU  - Haider R
JO  - Women's Health Science Journal
PY  - 2023
VL  - 7
IS  - 2
DO  - 10.23880/whsj-16000187
ER  -